Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of BMS-986196 in Healthy Participants
NCT04882150Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2021
- Primary completion
- Jun 2022
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 11c-bms-986196 in multiple sclerosis (MS) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of Adverse Events up to 24 days, Incidence of Serious Adverse Events up to 59 days and 3 more. Started May 2021; status: completed.
02
Drugs
11c-bms-986196
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04882150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04882150.